Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinopharm to Raise $640 Million in Bond Offering; Is M&A the Goal?

publication date: Mar 7, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
According to reports, Sinopharm Holdings, one of China’s big-three drug distributors, will issue 4 billion RMB ($640 million) five-year corporate bonds on the Shanghai Stock Exchange. The purpose? The company declared only a not-particularly-specific need to “replenish working capital.” Can we expect the transaction to spark new M&A activity in China’s highly fragmented drug distribution system? More details....

Stock Symbol: (HK: 01099)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors